8-KOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Corporate Update (Aug 11, 2005)

Filed August 11, 2005For Securities:BIIB

Summary

Biogen Idec Inc. filed an 8-K on August 11, 2005, to announce an update regarding the safety evaluation of its Multiple Sclerosis drug, TYSABRI® (natalizumab). The company disseminated a press release on August 9, 2005, which is incorporated by reference into this filing and included as an exhibit. This update likely provides crucial information for investors concerning the drug's ongoing safety profile and potential market impact. Investors should pay close attention to the details within the August 9, 2005 press release, as it will contain the specific findings and implications of the safety evaluation. Any developments related to TYSABRI® are significant given its therapeutic importance and market position. The filing itself is procedural, referencing the disseminated press release as the primary source of new information.

Key Highlights

  • 1Biogen Idec announced an update to the safety evaluation of TYSABRI® (natalizumab) via a press release on August 9, 2005.
  • 2The press release is officially incorporated by reference into the 8-K filing dated August 11, 2005.
  • 3Exhibit 99.1 of the filing contains the full text of the press release issued by Biogen Idec and Elan Corporation, plc.
  • 4This filing serves as an official notification of the safety update to the market and regulatory bodies.
  • 5The specific details of the safety evaluation update are contained within the referenced press release, not directly in the 8-K form itself.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and incorporate by reference a press release issued by Biogen Idec on August 9, 2005. This press release provides an update on the safety evaluation of TYSABRI® (natalizumab).

The detailed information regarding the TYSABRI® safety evaluation update is contained within the press release dated August 9, 2005, which is included as Exhibit 99.1 in this 8-K filing. Investors should review this press release for specifics.

The press release was issued by Biogen Idec Inc. and Elan Corporation, plc.

TYSABRI® (natalizumab) is a medication used for the treatment of Multiple Sclerosis, as indicated by the context of Biogen Idec's product portfolio and the nature of safety updates.